Skip to content

Alpha Mannosidosis Type 1 C2931251

Published: July 22, 2026Updated: August 20, 2026

A lysosomal storage disorder causing sugar buildup that damages cells, leading to intellectual disability and physical problems. Management includes supportive therapies and monitoring.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Hearing loss

(metabolic)

Recurrent infections

(metabolic)

Dysostosis multiplex

(metabolic)

Corneal clouding

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Enzyme replacement therapy

Infusion-based replacement of deficient alpha-mannosidase enzyme to reduce substrate accumulation in lysosomes. Requires regular administration typically every 2 weeks.

medication
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Hematopoietic stem cell transplantation

Bone marrow or cord blood transplant to provide cells capable of producing functional alpha-mannosidase enzyme. Carries significant risks but may provide long-term benefits.

surgical

Additional treatment options

Neuromuscular rehabilitation program

Structured physical therapy to maintain joint mobility, improve muscle strength, and address motor delays. Includes gait training and adaptive exercises.

physical_therapy

Comprehensive multidisciplinary monitoring

Regular assessments including neurology, ophthalmology, audiology, and developmental evaluations to track disease progression and adjust interventions.

monitoring

Symptomatic medication management

Pharmacological treatment of specific symptoms such as seizures, infections, and musculoskeletal pain using appropriate medications as symptoms arise.

medication

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alpha Mannosidosis Type 1 C2931251?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Malm D, Nilssen O, Borgwardt L. European recommendations for diagnosis and management of alpha-mannosidosis: consensus guidelines from the European Reference Network for Rare Hereditary Metabolic Disorders. Orphanet J Rare Dis. 2022.

guideline2022
2

Olson LJ, Bhattacharya SK. Alpha-mannosidosis: pathogenesis, clinical manifestations, and emerging therapeutic strategies. Mol Genet Metab. 2021.

review2021
3

Borgwardt L, Thuren T, Nordborg P. Enzyme replacement therapy in alpha-mannosidosis: results from a phase 2 clinical trial. J Inherit Metab Dis. 2020.

clinical_trial2020
4

Beck M, Olsen K, Harmatz P. Natural history and long-term outcomes in patients with alpha-mannosidosis: a multicenter cohort study. Orphanet J Rare Dis. 2019.

other2019

Medication Comparisons

Compare medications used to treat Alpha Mannosidosis Type 1 C2931251. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy